摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

7‑amino‑5‑(4‑flourophenyl)‑1,3‑dimethyl‑2,4‑dioxo‑1,3,4,5‑tetrahydro‑2H‑pyrano[2,3‑d]pyrimidine‑6‑carbonitrile | 294874-38-7

中文名称
——
中文别名
——
英文名称
7‑amino‑5‑(4‑flourophenyl)‑1,3‑dimethyl‑2,4‑dioxo‑1,3,4,5‑tetrahydro‑2H‑pyrano[2,3‑d]pyrimidine‑6‑carbonitrile
英文别名
7-amino-5-(4-fluorophenyl)-1,3-dimethyl-2,4-dioxo-1,3,4,5-tetrahydro-2H-pyrano[2,3-d]pyrimidine-6-carbonitrile;7-amino-5-(4-fluorophenyl)-1,3-dimethyl-2,4-dioxo-5H-pyrano[2,3-d]pyrimidine-6-carbonitrile
7‑amino‑5‑(4‑flourophenyl)‑1,3‑dimethyl‑2,4‑dioxo‑1,3,4,5‑tetrahydro‑2H‑pyrano[2,3‑d]pyrimidine‑6‑carbonitrile化学式
CAS
294874-38-7
化学式
C16H13FN4O3
mdl
——
分子量
328.303
InChiKey
ACBYBPHAAZITMX-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    230-232 °C
  • 沸点:
    556.3±60.0 °C(Predicted)
  • 密度:
    1.50±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.1
  • 重原子数:
    24
  • 可旋转键数:
    1
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.19
  • 拓扑面积:
    99.7
  • 氢给体数:
    1
  • 氢受体数:
    6

反应信息

  • 作为反应物:
    描述:
    7‑amino‑5‑(4‑flourophenyl)‑1,3‑dimethyl‑2,4‑dioxo‑1,3,4,5‑tetrahydro‑2H‑pyrano[2,3‑d]pyrimidine‑6‑carbonitrile原甲酸三乙酯 反应 8.0h, 以70%的产率得到(E)-ethyl N-[5-(4-fluorophenyl)-6-cyano-1,3-dimethyl-2,4-dioxo-2,3,4,5-tetrahydro-1H-pyrano[2,3-d]pyrimidin-7-yl]carboximidate
    参考文献:
    名称:
    Synthesis, antimicrobial activity and molecular docking studies of pyrano[2,3-d]pyrimidine formimidate derivatives
    摘要:
    成功合成了一系列十种多功能化的吡喃[2,3-d]嘧啶甲酰胺衍生物。所有合成的化合物均通过1H NMR、13C NMR、HRMS和FT-IR光谱分析进行了表征。所有合成的化合物均通过孔板法评估其抗菌活性,并通过肉汤微稀释法测定其对细菌和真菌菌株的最低抑菌浓度(MIC)。四种化合物表现出良好至优异的抗菌活性。通过对接研究评估了靶分子的理论结合模式,揭示了一种新的分子框架,以增强化合物的抗菌活性。报道了新型吡喃[2,3-d]嘧啶甲酰胺衍生物(10)的合成、表征、抗菌活性和分子对接研究。其中四种化合物表现出优异的活性。
    DOI:
    10.1007/s11164-015-2243-7
  • 作为产物:
    描述:
    1,3-二甲基巴比妥酸对氟苯甲醛丙二腈1,8-二氮杂双环[5.4.0]十一碳-7-烯 作用下, 以 为溶剂, 反应 0.08h, 以78%的产率得到7‑amino‑5‑(4‑flourophenyl)‑1,3‑dimethyl‑2,4‑dioxo‑1,3,4,5‑tetrahydro‑2H‑pyrano[2,3‑d]pyrimidine‑6‑carbonitrile
    参考文献:
    名称:
    1,8-二氮杂双环[5.4.0]十一月-7-烯:一种高效的催化剂,可在其中进行取代的四氢-4H-苯甲基,四氢[b]吡喃,吡喃并[d]嘧啶和4H-吡喃的一锅法合成水性介质
    摘要:
    我们已经报道了1,8-二氮杂双环[5.4.0]十一碳-7烯从醛催化一锅合成四氢-4 H-苯甲基,四氢[ b ]吡喃,吡喃并[ d ]嘧啶和4 H-吡喃。活性亚甲基化合物丙二腈/氰基乙酸乙酯和活化的C-H酸,如二甲酮,1,3-环己二酮,1,3-环戊烷二酮,1,3-二甲基巴比妥酸和乙酰乙酸乙酯在水中回流。该方法的吸引人的特征是温和的反应条件,反应介质的可重​​复使用性,较短的反应时间,易于分离的产物以及优异的产率。版权所有©2013 HeteroCorporation
    DOI:
    10.1002/jhet.1507
点击查看最新优质反应信息

文献信息

  • Effect of Liquid Glass Composition on the Catalytic Preparation of Pyrano[2,3-d]pyrimidine Derivatives
    作者:Mehdi Abaszadeh、Seyyed Jalal Roudbaraki、Majid Ghashang
    DOI:10.1080/00304948.2019.1600124
    日期:2019.5.4
    compounds containing at least one core moiety of pyrano[2,3-d]pyrimidine have received considerable attention in synthetic organic chemistry because of their potential as drugs and bioactive compounds. Pyrano[2,3-d]pyrimidines have attracted interest in medicine as antitumor, anti-hypertensive, antibacterial and antileishmanial drugs. Pyrano[2,3-d]pyrimidines have been produced by a number of methods. A
    本研究的主要目的是使用液态玻璃作为催化剂催化制备5-芳基-1,3,4,5-四氢2H-吡喃并[2,3-d]嘧啶-6-腈衍生物。所有反应均在中回流条件下进行。作为进一步的目标,使用高速球磨 (HSBM) 技术研究了该过程。研究了液态玻璃成分和添加金属氧化物杂质的影响。最近,含有至少一个喃并[2,3-d]嘧啶核心部分的化合物因其作为药物和生物活性化合物的潜力而在合成有机化学中受到了相当大的关注。喃并[2,3-d]嘧啶作为抗肿瘤、抗高血压、抗菌和抗利什曼病药物在医学上引起了人们的兴趣。喃并[2,3-d]嘧啶已通过多种方法生产。可以获得对合成程序的完整审查和关于这些化合物的讨论。分子式为 Na2(SiO2)nO 的液态玻璃是一种硅酸溶液,可通过 NaOH (25%) 与 SiO2 反应或通过将碳酸二氧化硅熔化来制备。数十年来,液态玻璃一直被用作粘合剂和涂层剂。液态玻璃是一种无毒、耐热
  • The first urea-based ionic liquid-stabilized magnetic nanoparticles: an efficient catalyst for the synthesis of bis(indolyl)methanes and pyrano[2,3-<i>d</i>]pyrimidinone derivatives
    作者:Mohammad Ali Zolfigol、Roya Ayazi-Nasrabadi、Saeed Baghery
    DOI:10.1002/aoc.3428
    日期:2016.5
    of bis(indolyl)methane derivatives via the condensation reaction between 2‐methylindole and aldehydes at room temperature under solvent‐free conditions. Also, pyrano[2,3‐d]pyrimidinone derivatives were prepared in the presence of the nanomagnetic urea‐based catalyst by the one‐pot three‐component condensation reaction of 1,3‐dimethylbarbituric acid, aldehydes and malononitrile under solvent‐free conditions
    基于尿素离子液体稳定在二氧化硅包覆的Fe 3 O 4磁性纳米颗粒上,Fe 3 O 4 @SiO 2 @(CH 2)3-尿素-SO 3H / HCl}是碱土中一种无与伦比的,平滑释放的尿素肥料,并通过傅立叶变换红外光谱,可见光和能量分散的X射线光谱,X射线衍射,扫描和透射电子显微镜,原子能对其进行了全面表征。力显微镜和热重分析。纳米结构催化剂是一种新型,绿色,高效的催化剂,它通过2-甲基吲哚与醛在室温下在无溶剂条件下的缩合反应用于合成双(吲哚基)甲烷生物。另外,喃并[2,3- d] pyrimidinone衍生物是在纳米磁性基催化剂存在下,在60°C无溶剂条件下,通过1,3-二甲基巴比妥酸,醛和丙二腈的单锅三组分缩合反应制备的。据我们所知,这是首次合成在二氧化硅包覆的Fe 3 O 4磁性纳米粒子上稳定的离子液体的报告。因此,当前的工作可以在合理设计,合成和应用特定任务的基于肥料
  • Synthesis, characterization and application of ZnFe<sub>2</sub>O<sub>4</sub>nanoparticles as a heterogeneous ditopic catalyst for the synthesis of pyrano[2,3-d] pyrimidines
    作者:Ardeshir Khazaei、Azam Ranjbaran、Fatemeh Abbasi、Marzieh Khazaei、Ahmad Reza Moosavi-Zare
    DOI:10.1039/c4ra16664g
    日期:——

    In the present work, ZnFe2O4nanopowder, as a highly efficient and heterogeneous catalyst, was prepared and fully characterized by IR, UV, XRD, EDX and SEM analysis.

    在目前的工作中,作为一种高效的非均相催化剂,ZnFe2O4纳米粉末通过红外、紫外、X射线衍射、能谱分析和扫描电子显微镜进行了全面表征。
  • Synthesis of pyrano[2,3‐d]pyrimidines and pyrido[2,3‐d]pyrimidines in the magnetized deionized water based on UV–visible study
    作者:Mohammad Bakherad、Ghadamali Bagherian、Amin Rezaeifard、Fatemeh Mosayebi、Behzad Shokoohi、Ali Keivanloo
    DOI:10.1007/s13738-020-02073-z
    日期:2021.4
    Abstract A green synthetic route to the facile one-pot multicomponent synthesis of pyrano[2,3d]pyrimidines and pyrido[2,3d]pyrimidines have been developed using magnetized deionized water (MDW) as a green solvent under catalyst-free conditions. All reactions carried out in a short period of time and the products are obtained in high-to-excellent yields. The developed synthetic technique offers numerous
    摘要 在无催化剂的情况下,使用磁化去离子(MDW)作为绿色溶剂,已经开发出一条绿色的合成路线,可以轻松实现一锅多位合成喃并[2,3- d ]嘧啶吡啶并[2,3- d ]嘧啶。情况。所有反应都在短时间内进行,并且以高至优异的产率获得了产物。与传统的合成方法相比,发达的合成技术具有许多优点,包括环保,清洁合成,简单,成本低,反应时间短,反应产率高以及后处理容易。此外,通过监测普通去离子和MDW中反应混合物的吸收光谱的变化,通过分光光度法跟踪反应速率。 图形摘要
  • Solvent-free multicomponent assembling of aldehydes, <i>N,N</i>′-dialkyl barbiturates and malononitrile: fast and efficient approach to pyrano[2,3-<i>d</i>]pyrimidines
    作者:Michail N. Elinson、Fedor V. Ryzhkov、Valentina M. Merkulova、Alexey I. Ilovaisky、Gennady I. Nikishin
    DOI:10.1515/hc-2014-0114
    日期:2014.10.1
    Abstract

    Potassium fluoride-catalyzed solvent-free multicomponent reaction of aldehydes, N,N′-dialkyl barbiturates and malononitrile results in the fast (15 min) and efficient (yields 89–95%) formation of substituted pyrano[2,3-d]pyrimidines. The improved synthetic methodology for this class of bioactive compounds is important from the viewpoint of diversity-oriented large-scale processes and represents an environmentally benign solvent-free synthetic concept for multicomponent reactions strategy.

    摘要:化物催化的无溶剂多组分反应,包括醛类、N,N'-二烷基戊二酰丙二腈,能够在短时间(15分钟)内高效(产率为89-95%)地形成取代的喷[2,3-d]嘧啶。这种改进的合成方法对于这类生物活性化合物而言非常重要,从多样性导向的大规模过程的角度来看,代表了一种环境友好的无溶剂多组分反应策略的合成概念。
查看更多

同类化合物

叔-丁基2-(甲磺酰)-5,7-二氢螺[吡喃并[4,3-D]嘧啶并-8,3-吡咯烷]-1-甲酸基酯 乙基7'-氨基-6-氟-2,2',4'-三羰基-1,1',2,2',3',4'-六氢螺[吲哚-3,5'-吡喃并[2,3-d]嘧啶]-6'-羧酸酯 7H-吡喃并[2,3-d]嘧啶-7-酮 7H-吡喃并[2,3-d]嘧啶 7,8-二氢-5H-吡喃并[4,3-D]嘧啶-2-胺 5H-吡喃并[4,3-d]嘧啶 5H-吡喃并[2,3-d]嘧啶 2H-吡喃并[2,3-d]嘧啶-6-甲腈,7-氨基-1,3,4,5-四氢-5-(4-甲氧苯基)-2,4-二羰基- 2,4-二氯-7,8-二氢-5H-吡喃[4,3-d]嘧啶 1H-吡喃并[3,4-d]嘧啶 1H-吡喃并[3,2-d]嘧啶 (5S,7R,8S)-2-methylsulfanyl-5,8-dihydro-7-allyloxymethyl-5-methoxy-pyrano[3,4-d]-pyrimidin-8-ol 5-ethyl-2-[(Z)-1-thiophen-3-ylpentylideneamino]oxy-3H-pyrano[2,3-d]pyrimidine-4,7-dione 5-ethyl-2-[[1-(3-methylbutanoyl)piperidin-4-ylidene]amino]oxy-3H-pyrano[2,3-d]pyrimidine-4,7-dione 5-butyl-2-[(E)-1-(4-cyclohexylpiperazin-1-yl)butylideneamino]oxy-3H-pyrano[2,3-d]pyrimidine-4,7-dione 2,3,3a,9-tetrahydro-5-iodo-2,3,3-trimethylimidazo[5,1-b][1,3]benzoxazin-1-one 2,4-dimethyl-9-methoxy-4,12b-dihydro-1H,7H-chromeno[4',3'-4,5]pyrano[2,3-d]pyrimidine-1,3(2H)-dione 5-methyl-3-{3-[(R)-2-oxo-3-(3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-6-yl)-oxazolidin-5-yl]-propyl}-1H-quinazoline-2,4-dione 7-amino-2-(benzothiazol-2-ylmethyl)-9-phenylthiazolo[4',5':6,5]pyrano[2,3-d]pyrimidine-8(7H)-one 2-[6-[(2-chlorophenyl)methyl]pyridin-2-yl]-7,8-dihydro-5H-pyrano[4,3-d]pyrimidine 8-amino-2-(methylthio)-5-oxo-6-(pyridin-4-yl)-5,6-dihydro-4H-pyrano[2,3-d][1,3]thiazolo[4,5-b]pyridine-7-carbonitrile 5-(4-chlorophenyl)-1,3,8,8-tetramethyl-7,9-dihydro-5H-chromeno[2,3-d]pyrimidine-2,4,6-trione ethyl 7'-amino-2,4'-dioxo-2'-thioxo-1,1',2,2',3',4'-hexahydrospiroindole-3,5'-pyrano[2,3-d]pyrimidine-6'-carboxylate 8-amino-2-(methylthio)-5-oxo-6-(pyridin-3-yl)-5,6-dihydro-4H-pyrano[2,3-d][1,3]thiazolo[4,5-b]pyridine-7-carbonitrile 7-Amino-4-oxo-5-phenyl-2-thioxo-1,3,4,5-tetrahydro-2H-pyrano[2,3-d]pyrimidine-6-carboxylic acid ethyl ester 3-(1H-benzoimidazol-2-yl)-3-butyl-5-methyl-dihydro-furan-2-one 3-(1H-benzoimidazol-2-yl)-3-(2-diethylamino-ethyl)-5-methyl-dihydro-furan-2-one 1-{4-[(1R,9S)-3-((S)-3-methyl-morpholin-4-yl)-12-oxa-4,6-diaza-tricyclo[7.2.1.0-2,7]dodeca-2(7),3,5-trien-5-yl]-phenyl}-3-oxetan-3-yl-urea (S)-6-(4-(4-(3-ethylmorpholino)-7,8-dihydro-5H-pyrano[4,3-d]pyrimidin-2-yl)phenylamino)pyridin-2(1H)-one 3-(1H-benzoimidazol-2-yl)-5-methyl-3-(3-methyl-butyl)-dihydro-furan-2-one 13-(3,4-dimethoxyphenyl)-5,5-dimethyl-2-thioxo-2,5,6,8,9,13-hexahydro-4H-pyrimido[5',4':6,7][1,8]naphthyridino[4,3,2-de]quinazoline-10,12(3a1H,11H)-dione (S)-3-allyl-8-ethyl-4,7-dioxo-2-(phenylcarbamoyl)-4,5,7,8-tetrahydro-3H-pyrano[4,3-d]pyrimidin-8-yl acetate 8-{[(2-bromo-3-methylphenyl)oxy]methyl}-1,3-dimethyl-2,3,4,6-tetrahydro-1H-pyrano[3,2-d]pyrimidine-2,4-dione 9-ethyl-6a-methyl-2-phenyl-8,9-dihydro-oxazolo[2,3-b]pyrimido[4,5-d][1,3]oxazin-5-one (S)-1-cyclobutyl-3-(4-(4-(3-methylmorpholino)-7,8-dihydro-5H-pyrano[4,3-d]pyrimidin-2-yl)phenyl)urea (S)-2-(4-(4-(3-ethylmorpholino)-7,8-dihydro-5H-pyrano[4,3-d]pyrimidin-2-yl)phenylamino)pyrimidin-4(3H)-one (6aRS,10aRS)-4,6,6a,7,8,9,10,10a-octahydro-2,4,6,6-tetramethyl-1H-<2>benzopyrano<3,4-d>pyrimidine-1,3(2H)-dione 5-ethyl-2-[(E)-1-thiophen-3-ylpentylideneamino]oxy-3H-pyrano[2,3-d]pyrimidine-4,7-dione N3-(methyl 4-deoxy-α-L-threo-hex-4-enopyranosyluronate)-5-fluorouracil 1-{4-[(1S,9R)-3-((S)-3-methyl-morpholin-4-yl)-12-oxa-4,6-diaza-tricyclo[7.2.1.0-2,7]dodeca-2(7),3,5-trien-5-yl]-phenyl}-3-oxetan-3-yl-urea 4,5-dimethyl-12-(4-methoxyphenyl)-2-thioxo-2,4a,7,8,9,10,11,12-octahydrodipyrimido[4,5-b;4',5'-f] [1,8]naphthyridine-9,11-dione 2-[4-[2-hydroxyethyl(methyl)amino]-2-methyl-7-oxopyrimido[5,4-b][1,4]oxazin-8-yl]acetonitrile 5-ethyl-2-[(Z)-1-thiophen-2-ylethylideneamino]oxy-3H-pyrano[2,3-d]pyrimidine-4,7-dione